RBC Capital has reiterated its bullish outlook on Biogen Inc. (NASDAQ:BIIB), maintaining a Buy recommendation and a price target of $208 following the company’s recent financial performance and future growth prospects. Analyst Brian Abrahams, in a report released on July 7, underscored Biogen’s strategic positioning as a driver of this optimism.

Biogen, recognized as one of the 13 cheap healthcare stocks with significant upside potential, recently reported total revenue of $2.4 billion, representing a 6% increase year-over-year. The company’s current market valuation stands at approximately two times sales and eight times earnings, metrics that RBC Capital views as suggestive of considerable room for stock appreciation as Biogen advances its turnaround strategy.

As of July 10, 2025, Abrahams continues to rate Biogen stock as Outperform, reaffirming the target price of $208. A particular focus for investors is the expected acceleration in adoption of Leqembi, an Alzheimer’s treatment, projected for 2026. Additionally, RBC Capital points to upcoming developments in Biogen's immunology and inflammation pipeline as key elements of the company's future growth. However, analysts warn that the company’s near-term prospects could be affected by results from Eli Lilly’s presymptomatic Alzheimer’s disease trial, which is anticipated to shape Biogen’s competitive standing in the Alzheimer’s market.

Business development activities are seen as critical to sustaining near-term growth, with RBC Capital stressing the importance of ongoing partnerships or acquisitions. The financial firm’s continued confidence in Biogen is also rooted in the company’s disciplined approach to value creation and strategic investments.

In the equity markets, Biogen Inc. is traded under the ticker BIIB. As of the latest session, the stock price stands at $133.65, reflecting a modest change of -$0.56 (or -0.00%) from its previous close. The day’s trading saw the stock open at $133.56, with an intraday low of $132.50 and a high of $134.31. Trading volume reached 188,940 shares, as of the most recent update at Monday, July 14, 16:41:15 UTC.

For further details on the report, see Investing.com.